Neurofibroma is a benign tumor originating from the peripheral nerve sheath, consisting of a heterogeneous mixture of Schwann cells, fibroblasts, perineural cells, and collagen fibers. It may be sporadic (90%) or associated with neurofibromatosis type 1 (NF1, von Recklinghausen disease) (10%). Superficial neurofibromas are located in dermis or subcutaneous tissue and may be solitary or multiple. Multiple cutaneous neurofibromas are diagnostic criteria for NF1 (6+ lesions). Clinically presents as soft, elastic, painless nodule with possible 'buttonhole sign' (central depression on palpation). Ultrasonography is the primary diagnostic modality — 'target sign' is pathognomonic: peripheral hyperechoic ring + central hypoechoic area.
Age Range
15-55
Peak Age
30
Gender
Equal
Prevalence
Uncommon
Neurofibroma results from neoplastic proliferation of Schwann cells in the peripheral nerve sheath; however, unlike schwannoma, the tumor grows WITHIN nerve fascicles and incorporates nerve fibers (infiltrative growth). Histologically contains Schwann cells, fibroblasts, perineural cells, mast cells, and abundant myxoid stroma (hyaluronic acid-rich extracellular matrix). NF1-associated neurofibromas result from inactivating mutations in the NF1 gene (17q11.2) — loss of neurofibromin (tumor suppressor) → excessive activation of RAS/MAPK pathway → uncontrolled cell proliferation. The anatomic basis of target sign reflects the tumor's internal architecture: central hypoechoic area represents dense cellular component + myxoid stroma (high water content → low acoustic impedance), while peripheral hyperechoic ring represents perineural fibrous capsule + peripheral nerve fibers (organized collagen → high impedance). This concentric arrangement appears as target sign on US. Myxoid stroma provides T2 hyperintense signal on MRI and contributes to posterior acoustic enhancement on US (low attenuation). Fusiform morphology reflects the tumor's growth orientation along the nerve axis — because it incorporates nerve fascicles, it cannot be surgically separated from the nerve (fundamental difference from schwannoma).
On transverse section, peripheral hyperechoic ring (perineural fibrous capsule/nerve fibers) + central hypoechoic area (cellular + myxoid stroma) is pathognomonic for neurofibroma. Most reliable finding for differentiating from schwannoma — target sign is not seen in schwannoma (more homogeneously hypoechoic). Seen in large lesions (70-80%). MRI shows 'reverse target sign' — central low signal + peripheral high signal — from the same histological structure imaged by different physical principles.
On B-mode US, neurofibroma shows the characteristic 'target sign' on transverse section: central hypoechoic area + peripheral hyperechoic ring. The central hypoechoic area reflects dense cellular component and myxoid stroma; the peripheral hyperechoic ring represents perineural fibrous capsule and peripheral nerve fibers. Target sign is pathognomonic for neurofibromas and is the most important US finding for differentiating from schwannoma. Target sign is seen in large lesions (70-80%); small lesions may show homogeneous hypoechoic appearance. Longitudinal section shows fusiform morphology and entering/exiting nerve ends (tail sign).
Report Sentence
Target sign consisting of central hypoechoic area and peripheral hyperechoic ring is seen on transverse section; pathognomonic for neurofibroma.
On longitudinal section, neurofibroma shows fusiform (spindle-shaped) morphology along the nerve course. At the proximal and distal ends of the lesion, the entering and exiting nerve is seen as a thin echogenic line — 'tail sign'. Tail sign is characteristic of nerve-origin tumors (seen in both neurofibroma and schwannoma). Neurofibroma grows from the center of the nerve (intraneural) — unlike schwannoma, it is not eccentric to the nerve. Lesion size is usually 1-5 cm with long axis parallel to the nerve course.
Report Sentence
A lesion with fusiform morphology along the nerve course is seen, with tail sign at proximal and distal ends.
Posterior acoustic enhancement is seen behind the neurofibroma — the high water content of myxoid stroma attenuates sound waves at a low rate → cyst-like enhancement. This finding is directly proportional to the prominence of the myxoid component — prominent enhancement in myxoid-rich lesions, minimal or absent in fibrous-dominant lesions. Posterior enhancement is a shared feature of neurofibroma and schwannoma and aids differentiation from other solid lesions (fibroma, dermatofibroma — no enhancement).
Report Sentence
Posterior acoustic enhancement is observed behind the lesion; consistent with myxoid component.
Neurofibroma generally shows minimal internal vascularity on color and power Doppler. Central or peripheral punctate vascular signals may be seen in some cases. This low vascularity reflects the slow-growing benign nature. Increased vascularity (especially in plexiform neurofibroma) should raise suspicion for more aggressive behavior or malignant peripheral nerve sheath tumor (MPNST) transformation. In NF1 patients, the risk of neurofibroma to MPNST transformation is 8-13%.
Report Sentence
Minimal vascular signal is detected within the lesion on Doppler; consistent with a benign nerve sheath tumor.
On MRI T2, neurofibroma shows heterogeneous hyperintensity. Myxoid component shows marked T2 hyperintensity, cellular component shows intermediate signal. In large lesions, MRI target sign — central low-intermediate signal (fibrous center) + peripheral high signal (myxoid periphery) — shows a reverse pattern from US target sign. This MRI target sign is highly characteristic for neurofibroma. Low-intermediate T1 signal. Enhancement is usually mild-moderate, heterogeneous. In plexiform neurofibroma, 'bag of worms' appearance — multiple fusiform thickenings along the nerve.
Report Sentence
A heterogeneously T2-hyperintense lesion with fusiform morphology along the nerve course is seen; consistent with neurofibroma.
Neurofibroma grows from the nerve center (intraneural) and incorporates nerve fascicles within the tumor. On US, the nerve passes through the neurofibroma — the lesion is concentric rather than eccentric to the nerve. This feature is critical for differentiating from schwannoma: schwannoma is eccentric and displaces the nerve. In neurofibroma, nerve fascicles may be seen as small hypoechoic lines dispersed within the tumor. Surgically important — neurofibroma cannot be separated from the nerve, fascicle sacrifice may be necessary.
Report Sentence
The lesion grows from within the nerve (intraneural) and incorporates nerve fascicles; consistent with neurofibroma.
Criteria
Solitary, small (<3 cm), dermal/subcutaneous, not associated with NF1.
Distinct Features
Most common (90%). Malignant transformation risk very low (<1%). Excision is curative, recurrence rare.
Criteria
Multiple (6+), NF1 diagnostic criterion, number increases at puberty, may grow during pregnancy.
Distinct Features
May coexist with café-au-lait spots, Lisch nodules, optic glioma. MPNST transformation risk high (8-13% lifetime). PET-CT surveillance.
Criteria
Diffuse growth involving multiple nerve segments along nerve plexus. NF1-specific.
Distinct Features
'Bag of worms' on MRI. Highest MPNST transformation risk (5-10%). May be inoperable. MEK inhibitors (selumetinib) FDA-approved.
Distinguishing Feature
Schwannoma is eccentric to nerve (pushes aside, does not infiltrate), no target sign (homogeneously hypoechoic), prominent posterior enhancement and may contain cystic degeneration. Neurofibroma grows centrally within nerve (intraneural), target sign is pathognomonic, and cannot be surgically separated from nerve.
Distinguishing Feature
Dermatofibroma is within dermis, no nerve association, shows dimple sign, no posterior enhancement, no target sign. Neurofibroma is nerve-associated, identified by tail sign and target sign.
Distinguishing Feature
Ganglion cyst is anechoic/hypoechoic cystic, compressible, joint/tendon sheath-connected, avascular. Neurofibroma is solid, non-compressible, nerve-associated with target sign.
Urgency
routineManagement
conservativeBiopsy
Not NeededFollow-up
12-monthSporadic cutaneous neurofibroma is benign with very low malignant transformation risk (<1%). Diagnosis is made with typical US findings (target sign, fusiform, tail sign) without biopsy. Asymptomatic lesions do not require follow-up. Excision may be planned for pain, cosmetic, or functional issues — but nerve sacrifice may be needed since neurofibroma cannot be separated from nerve. In NF1 patients, annual MRI surveillance and urgent PET-CT + biopsy for rapid growth/pain change is recommended due to MPNST risk (8-13% lifetime). MEK inhibitors (selumetinib, 2020 FDA approval) are available for plexiform neurofibromas.
Solitary neurofibromas are benign and require no treatment if asymptomatic. During surgical excision, there is risk of nerve damage as the tumor cannot be separated from nerve fascicles (unlike schwannoma). In NF1 patients, multiple neurofibromas carry risk of malignant transformation — 8-13% of plexiform neurofibromas transform to MPNST. Rapid growth, increasing pain, or development of neurological deficit indicates malignant transformation — requires urgent biopsy and MRI evaluation. PET-CT is helpful in assessing malignant transformation in lesions >5 cm.